Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
See the separate, general article on Eosinophilia.
Hypereosinophilic syndrome (HES) is currently defined as a blood eosinophil count >1.5 x 109/L (for more than six months) and associated organ damage in the absence of secondary causes; it is categorised under the idiopathic group of eosinophilias. However, changes to this definition have been proposed based on recent studies identifying specific cellular and molecular disease phenotypes. This may have clinical and therapeutic significance.
Due to the increasing availability of treatments, for example, it is unlikely that a patient would be left without therapy for six months whilst organ damage occurred. Furthermore, individuals with eosinophilia-related complications (eg, eosinophilic pneumonia) have been discovered who do not meet the criteria of an eosinophil level >1.5 x 109/L. Finally, a secondary cause has been identified in some patients (eg, Fip1-like-1 (FIP1L1)/platelet-derived growth factor receptor alpha (PDGFRA)-associated HES).Despite these advances the molecular pathogenesis remains unknown in most cases.
The most up-to-date consensus definition was published by the Year 2011 Working Conference on Eosinophil Disorders and Syndromes, as follows:
- Criteria for peripheral blood hypereosinophilia (>0.5-1.5 × 109/L) fulfilled; and
- Organ damage and/or dysfunction attributable to tissue hypereosinophilia; and
- Exclusion of other disorders or conditions as major reason for organ damage.
- HES is rare in adults and tends to be under-diagnosed. It is even rarer in children.There are no formal patient registers and lack of published data makes estimates of prevalence difficult.
- HES can present anywhere from the age of 20 to 50 years.
- HES has a preponderance in males (4-9:1).
History and examination
HES can only be diagnosed once secondary causes and clonal eosinophilias have been ruled out. Document all medications, including herbal remedies and over-the-counter medicines and any recent travel. A full and thorough examination is needed, as the list of potential organs involved and the pathologies in each system are numerous.
The diagnosis of HES is not always straightforward - eg, differentiating between idiopathic eosinophilia with organ involvement and eosinophilia associated with a systemic vasculitis. In order to diagnose HES, clonal eosinophilia, ie neoplastic proliferation of eosinophils, also needs to be excluded. This can be seen in a number of myeloid malignancies or as an eosinophilic leukaemia. Exclusion of clonal eosinophilia will usually require investigations similar to any suspected bone marrow (BM) neoplasia - eg, peripheral blood smear, BM examination and cytogenetic studies.
If all these tests are negative then idiopathic eosinophilia is the likely diagnosis - the most important subcategory of which is HES.
The history and examination needs to be very thorough due to the multisystem nature of HES.
- Generalised symptoms - fatigue, aches and pains, fever, night sweats and pruritus.
- Diarrhoea is common, as are abdominal pain and nausea.
- Other symptoms depend on which organ is involved and extent of involvement; for example:
- Cardiac - chest pain and breathlessness.
- Respiratory - shortness of breath, and dry cough.
- Alcohol intolerance with abdominal pain, flushing, and nausea.
Organ involvement in HES
This can be manifold and the following are some examples:
- Blood - thrombocytopenia, hypercoagulability.
- Cardiac - cardiomyopathy, valve abnormalities, pericardial effusion, thromboembolic disease.
- Respiratory - pneumonitis, pulmonary emboli, pleural effusion and eosinophilic infiltrates.
- Skin - dermatitis, urticaria, papular rashes.
- Ear, nose and throat - sinusitis.
- Central nervous system - acute cerebrovascular event and peripheral neuropathy.
- Gastrointestinal tract - tract inflammation, infarction of the gut secondary to emboli, splenomegaly, ascites, hepatitis, pancreatitis.
- Neurological - acute cerebrovascular accident, confusion, ataxia, peripheral neuropathy.
- Eyes - episcleritis, retinal thrombi.
- FBC - eosinophils >1.5 x 109/L (0.5 x 109/L under the new definition); neutrophilia and anaemia are also common. Platelet counts can be high or low.
- Peripheral smear - eosinophils may have cytoplasmic vacuolisation and nuclear hypersegmentation and there may also be nucleated erythrocytes.
- ESR - usually raised.
- U&E and LFTs may both be abnormal.
- 12-lead ECG - may show conduction defects or inverted T waves.
- CXR - look for pleural effusions.
Further tests should be tailored towards the presenting symptoms and signs - eg, echocardiogram, further lung imaging, biopsy of endocardium, skin or BM..
An algorithm has been developed to assist in the differentiation between clonal eosinophilia, haematological malignancies and idiopathic eosinophilia. This involves peripheral blood screening for genetic abnormalities, BM cytogenetics , peripheral blood lymphocyte phenotyping and T-cell receptor gene rearrangement studies.
- The rarity of HES means there are no evidence-based guidelines on management. Management is aimed at reducing tissue and blood eosinophils and monitoring and restricting organ damage - eg, regular echocardiographic and serum troponin monitoring.
- Corticosteroids are first-line - eg, prednisolone with hydroxyurea or interferon alpha as second-line agents. If these also fail, or the monoclonal antibodies, such as mepolizumab (not licensed yet) and alemtuzumab, may be useful.
- Allogeneic hematopoietic cell transplant may be a treatment option in refractory HES.
Other generic measures may include anticoagulants, and symptomatic relief agents - eg, histamines and opiates. Other treatment will depend upon the organs involved - eg, diuretics in cardiac failure.
Prognosis in hypereosinophilic syndrome
- Good prognostic factors include response to prednisolone and lack of systemic symptoms.
- Poor prognosis is associated with anaemia, thrombocytopenia and organ involvement at time of presentation.
- The five-year survival rate is 80% with congestive heart failure being the most common cause of death.
- Leukaemic change is a risk in prolonged disease.
Further reading and references
Lim KS, Ko J, Lee SS, et al; A case of idiopathic hypereosinophilic syndrome presenting with acute respiratory distress syndrome. Allergy Asthma Immunol Res. 2014 Jan6(1):98-101. doi: 10.4168/aair.2014.6.1.98. Epub 2013 Sep 27.
Jiang P, Wang C, Jin B, et al; Eosinophilic cystitis in a patient with hypereosinophila syndrome: A case report. Exp Ther Med. 2014 Jul8(1):49-51. Epub 2014 May 12.
Hsieh FH; Hypereosinophilic syndrome. Ann Allergy Asthma Immunol. 2014 Jun112(6):484-8. doi: 10.1016/j.anai.2014.03.004. Epub 2014 Apr 13.
Simon HU, Rothenberg ME, Bochner BS, et al; Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010 Jul126(1):45-9. doi: 10.1016/j.jaci.2010.03.042.
Valent P, Klion AD, Horny HP, et al; Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012 Sep130(3):607-612.e9. doi: 10.1016/j.jaci.2012.02.019. Epub 2012 Mar 28.
Roufosse FE, Goldman M, Cogan E; Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007 Sep 112:37.
Katz HT, Haque SJ, Hsieh FH; Pediatric hypereosinophilic syndrome (HES) differs from adult HES. J Pediatr. 2005 Jan
Tefferi A, Gotlib J, Pardanani A; Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010 Feb85(2):158-64. Epub 2010 Jan 6.